Phases of biomarker development

被引：0
|
作者：
Etzioni, R [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2003年 / 12卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1356S / 1356S
页数：1
相关论文
共 50 条
  • [41] Biomarker development: muddy waters
    Pass, Harvey, I
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S7 - S7
  • [42] Pathology and Imaging in Biomarker Development
    Jaffe, C. Carl
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2009, 133 (04) : 547 - 549
  • [43] Biomarker development for axial spondyloarthritis
    Matthew A. Brown
    Zhixiu Li
    Kim-Anh Lê Cao
    Nature Reviews Rheumatology, 2020, 16 : 448 - 463
  • [44] The MethDet: a technology for biomarker development
    Levenson, Victor V.
    Melnikov, Anatoliy A.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2011, 11 (08) : 807 - 812
  • [45] A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment
    Taube, Sheila E.
    Clark, Gary M.
    Dancey, Janet E.
    McShane, Lisa M.
    Sigman, Caroline C.
    Gutman, Steven I.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (21): : 1453 - 1463
  • [46] Biomarker development for axial spondyloarthritis
    Brown, Matthew A.
    Li, Zhixiu
    Cao, Kim-Anh Le
    NATURE REVIEWS RHEUMATOLOGY, 2020, 16 (08) : 448 - 463
  • [47] Mass spectrometry and biomarker development
    Rodland, KD
    DISEASE MARKERS, 2004, 20 (03) : 129 - 130
  • [48] How to synchronize biomarker development with early drug development?
    Harris, AL
    ANNALS OF ONCOLOGY, 2005, 16 : 26 - 26
  • [49] The national biomarker development alliance: An end-to-end systems approach for biomarker development for precision medicine
    Compton, Carolyn C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] The primary phases of the development of leukocytes of crustaceans
    Besson
    de Lavergne
    COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES, 1921, 84 : 810 - 811
12345